ArticleFrontiers in psychiatry2025
Association between homocysteine levels and cognition in late-life depression.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Homocysteine and cognitive function in depression: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Homocysteine as a biomarker in arthritis and depression: Evidence from NHANES and gene expression studies.SAGE open medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment frequently occurs in patients with late-life depression (LLD) and could be associated with variations in homocysteine (Hcy) levels. This study aimed to evaluate the relationship between Hcy levels and cognitive function, with particular attention on how baseline cognitive status may impact this relationship. Methods: This cross-sectional study included 60 patients with LLD meeting Diagnostic and Statistical Manual of Mental Disorders, V Edition (DSM-5) diagnostic criteria and 46 age-matched healthy controls (HCs). Participants were excluded if they had severe physical illnesses. Cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scale and Mini-Mental State Examination (MMSE). Hcy levels were determined. Results: Compared to HCs, LLD patients demonstrated significant impairment across all RBANS subdomains except language ( Limitations: The small sample size and lack of ethnic diversity may limit the generalizability of our results. Conclusion: Patients with LLD often exhibit cognitive impairment and elevated Hcy levels. Notably, the association between Hcy and cognitive function is influenced by the patients' baseline cognitive status. This study offers novel insights into the mechanisms underlying cognitive impairment in patients with depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.